AmplifyBio Partners with Lipid Nanoparticle Expert to Enhance Drug Delivery

WEST JEFFERSON, OH / ACCESSWIRE / July 30, 2024 / AmplifyBio, a leader in mRNA discovery, development, and manufacturing, has announced a partnership with lipid nanoparticles (LNPs) specialist Stephen Burgess, Ph.D., from AvaBurg LLC. This collaboration aims to improve the encapsulation, protection, and delivery of mRNA to cells.

Dr. Burgess, with over 33 years of experience in lipid chemistry, previously served as Chief Scientific Officer at Avanti Polar Lipids. He will assist AmplifyBio with lipid formulation, regulatory compliance, and stability considerations, ensuring efficient delivery of mRNA therapeutics.

Victoria Best, Sr. Director of Scientific Strategy and Innovation at AmplifyBio, highlighted Dr. Burgess's extensive expertise in lipid-based technologies as a key asset. Dr. Burgess expressed enthusiasm for addressing the challenges in optimizing LNP delivery performance alongside AmplifyBio.

This partnership follows AmplifyBio's recent collaboration with RNAV8 Bio and strengthens their capacity for high-throughput and GMP clinical-stage mRNA manufacturing at their New Albany, Ohio facility.